{"product_id":"lilly-business-model-canvas","title":"Eli Lilly Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic genius behind Eli Lilly's success with our comprehensive Business Model Canvas. Discover how they connect with key customer segments, forge vital partnerships, and deliver groundbreaking value propositions. This in-depth analysis is your key to understanding their competitive edge.\u003c\/p\u003e\n\u003cp\u003eReady to dissect Eli Lilly's winning formula? Our full Business Model Canvas breaks down their revenue streams, cost structure, and core activities, offering actionable insights for your own business ventures. Download the complete, professionally crafted document today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly actively collaborates with leading academic and research institutions to drive scientific advancement and accelerate drug discovery.\u003c\/p\u003e\n\u003cp\u003eA notable example is the expanded alliance with Purdue University, involving a planned investment of up to $250 million over eight years to accelerate innovation across the pharmaceutical pipeline.\u003c\/p\u003e\n\u003cp\u003eThis partnership aims to bridge the gap between laboratory discoveries and clinical applications, fostering the next generation of pharmaceutical professionals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Companies for R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly actively cultivates key partnerships with biotechnology companies to bolster its early-stage research and development pipeline. These alliances are crucial for accessing and exploring novel therapeutic approaches and cutting-edge drug candidates. \u003c\/p\u003e\n\u003cp\u003eA prime example of this strategy is Eli Lilly's agreement with Gate Bioscience, a deal valued at up to $856 million, aimed at developing a new generation of small-molecule drugs. This collaboration underscores Lilly's dedication to leveraging external innovation to drive its R\u0026amp;D efforts. \u003c\/p\u003e\n\u003cp\u003eThese strategic collaborations typically involve a mix of licensing agreements and equity investments. Such structures allow Eli Lilly to gain access to innovative platforms and promising drug candidates, thereby accelerating the development of potential new medicines. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly relies on Contract Manufacturing Organizations (CMOs) to boost production of its popular drugs, especially GLP-1 treatments like Mounjaro and Zepbound, which are experiencing massive demand.  This allows Lilly to scale up manufacturing quickly to meet the surging patient needs.\u003c\/p\u003e\n\u003cp\u003eWhile Lilly is heavily investing in its own manufacturing facilities, these external partnerships are crucial for navigating the intricate global supply chain and getting vital medicines to market faster.  For instance, in 2024, Lilly announced significant expansion plans with CMOs to address the overwhelming demand for its obesity and diabetes medications.\u003c\/p\u003e\n\u003cp\u003eThis approach provides essential flexibility and scalability in production, enabling Eli Lilly to respond effectively to market fluctuations and ensure a consistent supply of its life-changing therapies to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telehealth Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly is enhancing its patient access and support by forging key partnerships with digital health and telehealth providers. This strategic move is designed to streamline how patients receive their medications and engage with healthcare services.\u003c\/p\u003e\n\u003cp\u003eA prime example is the launch of LillyDirect, a direct-to-consumer platform. This initiative allows patients to manage prescriptions, access telehealth consultations, and receive medications directly at their homes, creating a more convenient and integrated experience. In 2024, the telehealth market continued its significant growth, with projections indicating further expansion in the coming years, underscoring the importance of these digital health collaborations for pharmaceutical companies like Eli Lilly.\u003c\/p\u003e\n\u003cp\u003eEli Lilly is also collaborating with established players in the digital pharmacy space. By teaming up with entities such as Amazon Pharmacy, Eli Lilly is leveraging third-party dispensing capabilities. This partnership facilitates online prescription fulfillment and direct medication delivery, further simplifying the patient journey and expanding reach.\u003c\/p\u003e\n\u003cp\u003eThese partnerships enable several key benefits for Eli Lilly and its patients:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Patient Convenience:\u003c\/strong\u003e Offering online prescriptions, telehealth consultations, and direct-to-door delivery simplifies medication management.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpanded Reach:\u003c\/strong\u003e Collaborations with digital health platforms and online pharmacies broaden access to Eli Lilly's treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStreamlined Distribution:\u003c\/strong\u003e Utilizing third-party dispensing providers like Amazon Pharmacy optimizes the medication supply chain.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved Patient Engagement:\u003c\/strong\u003e Digital platforms facilitate better communication and support for patients throughout their treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Non-Profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly actively partners with patient advocacy groups and non-profits to tackle significant unmet medical needs and advance global health. These collaborations are crucial for driving initiatives that improve patient education, facilitate earlier diagnosis, and broaden access to essential treatments, particularly in underserved communities.\u003c\/p\u003e\n\u003cp\u003eA prime example of this commitment is Eli Lilly's ambitious Lilly 30x30 goal, which aims to positively impact the lives of 30 million people annually in resource-limited settings by 2030. This goal is often realized through strategic alliances with organizations like UNICEF, underscoring the power of shared purpose in achieving widespread healthcare improvements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Education and Awareness:\u003c\/strong\u003e Collaborations enhance public understanding of diseases and treatment options.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess to Care:\u003c\/strong\u003e Partnerships improve the availability of diagnostics and therapies, especially in underserved regions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Health Initiatives:\u003c\/strong\u003e Joint efforts address critical health challenges, aligning with Lilly's 30x30 goal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearch and Development Support:\u003c\/strong\u003e Advocacy groups can provide valuable insights into patient needs, guiding R\u0026amp;D priorities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Partnerships Drive Innovation and Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly's key partnerships are vital for its innovation and market reach. Collaborations with academic institutions like Purdue University, with a planned investment of up to $250 million over eight years, fuel early-stage research and development. Strategic alliances with biotech firms, such as the up to $856 million deal with Gate Bioscience, secure access to novel drug candidates. Furthermore, partnerships with Contract Manufacturing Organizations (CMOs) are crucial for scaling production of high-demand drugs like Mounjaro and Zepbound, ensuring supply meets soaring patient needs.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA detailed exploration of Eli Lilly's approach to drug discovery, development, and commercialization, focusing on its key customer segments, value propositions, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eThis model highlights Eli Lilly's strategic partnerships, R\u0026amp;D investments, and global distribution channels to deliver innovative healthcare solutions to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eEli Lilly's Business Model Canvas acts as a pain point reliever by mapping out its value proposition of innovative drug development and patient access, directly addressing the pain points of unmet medical needs and treatment accessibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly's commitment to Research and Development is a cornerstone of its business model, driving the discovery and delivery of groundbreaking treatments.  In 2024, the company significantly boosted its R\u0026amp;D investment, reaching $10.99 billion, an 18% increase from the previous year. This substantial funding fuels innovation across critical therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThe company's R\u0026amp;D efforts are strategically concentrated on key areas such as diabetes, oncology, immunology, and neuroscience. By consistently advancing its pipeline through new data readouts and clinical trials, Eli Lilly aims to address significant unmet medical needs and bring novel solutions to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly is significantly expanding its global manufacturing and supply chain operations to address the surging demand for its innovative medicines, especially its GLP-1 products. This strategic move involves substantial capital investments to bolster production capacity. \u003c\/p\u003e\n\u003cp\u003eSince 2020, Eli Lilly has committed over $50 billion to capital expansion within the United States. This investment includes the development of new facilities dedicated to producing active pharmaceutical ingredients and injectable therapies, ensuring a robust supply chain. \u003c\/p\u003e\n\u003cp\u003eThe company is actively bringing additional manufacturing capacity online. This expansion is crucial for producing a substantially higher volume of sellable doses in the upcoming years, directly supporting the growing patient need for its treatments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly’s key activities heavily revolve around the meticulous execution of clinical trials. These trials are the bedrock for substantiating the safety and effectiveness of their innovative drug candidates, a process that demands significant investment and expertise.\u003c\/p\u003e\n\u003cp\u003eSecuring regulatory approvals is paramount. For instance, the anticipated FDA approval of Zepbound for obstructive sleep apnea and Omvoh for Crohn's disease, expected in late 2024 or early 2025, represents critical milestones. These approvals are not just checkboxes; they are gateways to market access and revenue generation.\u003c\/p\u003e\n\u003cp\u003eThese rigorous clinical trial processes and successful regulatory navigation are indispensable for bringing new medicines to patients and for expanding the approved uses of existing treatments, directly impacting Lilly’s product portfolio and market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing, Sales, and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly directs significant resources toward marketing and sales, aiming to educate healthcare professionals and patients about its innovative therapies. This includes robust promotional campaigns for key products such as Zepbound and Mounjaro, which are driving substantial revenue growth. For instance, Zepbound, approved in late 2023, saw rapid uptake, contributing to Lilly's strong performance in early 2024. \u003c\/p\u003e\n\n\u003cp\u003eThe company's selling and administrative expenses reflect these intensive marketing and sales activities. In the first quarter of 2024, Eli Lilly reported selling, general, and administrative expenses of $2.5 billion, an increase driven by these efforts. This investment is crucial for building awareness and ensuring patient access to new treatments.\u003c\/p\u003e\n\n\u003cp\u003eEli Lilly also oversees a sophisticated global distribution network. This complex system ensures that its medicines are delivered efficiently and safely to pharmacies, hospitals, and ultimately, patients across numerous countries. Managing this supply chain is vital for meeting the demand generated by its successful marketing and sales initiatives.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing \u0026amp; Sales Focus:\u003c\/strong\u003e Promoting new drug launches like Zepbound and Mounjaro to healthcare providers and patients globally.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Impact:\u003c\/strong\u003e Increased selling and administrative expenses, with Q1 2024 SG\u0026amp;A reaching $2.5 billion, reflecting promotional investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Network:\u003c\/strong\u003e Managing a complex, worldwide system to ensure timely and safe delivery of medicines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Drivers:\u003c\/strong\u003e Successful marketing and sales efforts are directly linked to the rapid adoption and revenue generation from key products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly's core operations revolve around rigorous intellectual property management and defense. Protecting its innovations through patents is paramount, ensuring market exclusivity for its branded pharmaceuticals and enabling the recoupment of substantial research and development expenditures. This proactive strategy is crucial for maintaining profitability and funding future drug discovery.\u003c\/p\u003e\n\u003cp\u003eThe company actively litigates to defend its patent portfolio against challenges from generic manufacturers and compounding pharmacies. For instance, in 2023, Eli Lilly was involved in numerous patent disputes concerning its key products, demonstrating a commitment to safeguarding its market position. These legal battles are essential for preserving the revenue streams generated by its novel therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Eli Lilly secures patents to protect its innovative drug formulations and manufacturing processes, granting it exclusive rights for a specified period.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLitigation and Enforcement:\u003c\/strong\u003e The company engages in legal actions to prevent unauthorized production or sale of generic versions of its patented drugs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment Justification:\u003c\/strong\u003e Robust IP defense ensures a return on the billions invested annually in research and development, fueling the pipeline of new medicines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Exclusivity:\u003c\/strong\u003e Maintaining patent protection allows Eli Lilly to command premium pricing for its branded products, a critical factor in its financial performance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Activities Propelling a Pharmaceutical Leader's Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly's key activities are deeply rooted in its robust research and development pipeline, focusing on innovation in therapeutic areas like diabetes, oncology, and neuroscience. The company significantly increased its R\u0026amp;D investment to $10.99 billion in 2024, an 18% rise year-over-year, to fuel these advancements and address unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eManufacturing and supply chain expansion are critical, with over $50 billion committed to US capital expansion since 2020, including new facilities for active pharmaceutical ingredients and injectable therapies to meet surging demand for products like Zepbound and Mounjaro.\u003c\/p\u003e\n\u003cp\u003eClinical trial execution and securing regulatory approvals, such as anticipated 2024\/2025 approvals for Zepbound and Omvoh, are vital for market access and revenue generation, directly impacting the company's product portfolio.\u003c\/p\u003e\n\u003cp\u003eAggressive marketing and sales efforts for key products like Zepbound and Mounjaro are essential revenue drivers, supported by $2.5 billion in Q1 2024 selling, general, and administrative expenses, alongside managing a sophisticated global distribution network.\u003c\/p\u003e\n\u003cp\u003eIntellectual property defense, including patent litigation to protect market exclusivity for its branded pharmaceuticals, is a core activity ensuring a return on R\u0026amp;D investment and maintaining profitability, as evidenced by numerous patent disputes in 2023.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Eli Lilly Business Model Canvas preview you're seeing is the actual, complete document you will receive upon purchase. This means the structure, content, and formatting are identical to what you'll download, ensuring no surprises and immediate usability. You're getting a direct look at the professional analysis you'll be able to edit and utilize right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611363033465,"sku":"lilly-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lilly-business-model-canvas.png?v=1754756131","url":"https:\/\/growthsharematrix.com\/products\/lilly-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}